Karyopharm Therapeutics Inc. (KPTI) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning. My name is Anas, and I'll be your conference operator today. At this time, I would like to welcome everyone to CarioFarm's Therapeutics Second Quarter 2026 Financial Results Conference Call. There will be a question and answer session to follow. Please be advised that this call is being recorded at the company's request. I would now like to turn the conference over to Brendan Strong, Senior Vice President, Investor Relations. Good morning, and thank you all for joining us on today's conference call to discuss CarioFarm's Second Quarter 2026 Financial Results, and recent company progress. We issued a press release this morning detailing our financial results for the second quarter of 2026. This release, along with the slide presentation that we will reference during our call today, are available on our website. For today's call, as shown on slide two, I'm joined by Richard, Reshma, Sohania and Lori, who will review our second quarter financial results, provide an update on the significant progress we've made advancing our myelofibrosis program Discuss the clinical and regulatory momentum supporting our planned S&DA submission, and review our financial position and capital allocation priorities. Before we begin our formal comments, I'll remind you that various remarks we will make today constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995, as outlined on slide 3. Actual results may differ materially from those indicated by these forward-looking statements, Thank you for joining us. You should not rely on these forward-looking statements as representing our views as of any later date. I'll now turn the call over to Richard. Please turn to slide five. Thank you, Brendan, ...